Annovis Bio IncNYSE:ANVS
- LAST PRICE15.8800
- TODAY'S CHANGE (%)0.6300 (4.1311%)
- Bid / Lots15.2000/ 5
- Ask / Lots16.5900/ 70
- Open / Previous Close15.5479 / 15.2500
- Day Range
- 52 Week Range
- Volume59,793
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ANVS |
|---|---|---|
| 09:32 ET | 370 | 15.54 |
| 09:52 ET | 313 | 15.5 |
| 09:56 ET | 900 | 15.5828 |
| 09:57 ET | 1900 | 15.53 |
| 10:01 ET | 150 | 15.83 |
| 10:06 ET | 400 | 15.83 |
| 10:08 ET | 370 | 15.8356 |
| 10:10 ET | 429 | 15.9999 |
| 10:12 ET | 1185 | 16.12 |
| 10:19 ET | 100 | 16.1398 |
| 10:21 ET | 246 | 16.0848 |
| 10:30 ET | 200 | 15.8801 |
| 10:33 ET | 100 | 15.88 |
| 10:35 ET | 100 | 15.87 |
| 10:37 ET | 200 | 15.89 |
| 10:42 ET | 200 | 15.9873 |
| 10:44 ET | 200 | 15.99 |
| 10:57 ET | 300 | 15.9534 |
| 11:00 ET | 198 | 15.97 |
| 11:04 ET | 300 | 16 |
| 11:08 ET | 190 | 15.9817 |
| 11:20 ET | 100 | 15.9 |
| 11:22 ET | 200 | 15.9 |
| 11:24 ET | 500 | 15.89 |
| 11:26 ET | 200 | 15.89 |
| 11:36 ET | 800 | 15.8699 |
| 11:38 ET | 200 | 15.87 |
| 11:42 ET | 104 | 15.8585 |
| 11:45 ET | 103 | 15.8256 |
| 11:47 ET | 100 | 15.9 |
| 11:49 ET | 595 | 15.98 |
| 12:09 ET | 200 | 15.96 |
| 12:16 ET | 880 | 15.96 |
| 12:18 ET | 320 | 15.98 |
| 12:27 ET | 787 | 16.1 |
| 12:30 ET | 350 | 16.12 |
| 12:36 ET | 495 | 16.2701 |
| 12:38 ET | 220 | 16.115 |
| 12:45 ET | 500 | 16.16 |
| 12:48 ET | 820 | 16.16 |
| 12:54 ET | 197 | 16.17 |
| 01:08 ET | 100 | 16.28 |
| 01:32 ET | 200 | 16.175 |
| 01:44 ET | 100 | 16.3461 |
| 01:48 ET | 530 | 16.2 |
| 02:20 ET | 200 | 16.12 |
| 02:24 ET | 400 | 15.9486 |
| 02:26 ET | 100 | 16.3612 |
| 02:27 ET | 100 | 16.2409 |
| 02:29 ET | 200 | 16.15 |
| 02:49 ET | 3000 | 16.22 |
| 03:03 ET | 300 | 16.21 |
| 03:14 ET | 1200 | 15.95 |
| 03:18 ET | 200 | 16.24 |
| 03:20 ET | 1346 | 16.2407 |
| 03:21 ET | 190 | 16.25 |
| 03:23 ET | 6109 | 16.7199 |
| 03:25 ET | 225 | 16.7199 |
| 03:27 ET | 525 | 16.5 |
| 03:30 ET | 3207 | 16.65 |
| 03:32 ET | 2600 | 16.4596 |
| 03:34 ET | 100 | 16.325 |
| 03:36 ET | 4304 | 16.19 |
| 03:38 ET | 200 | 16.18 |
| 03:39 ET | 100 | 15.96 |
| 03:41 ET | 400 | 15.94 |
| 03:43 ET | 200 | 15.955 |
| 03:45 ET | 500 | 16 |
| 03:48 ET | 750 | 15.98 |
| 03:50 ET | 500 | 15.94 |
| 03:52 ET | 500 | 15.94 |
| 03:54 ET | 808 | 16.075 |
| 03:56 ET | 900 | 15.95 |
| 03:57 ET | 1150 | 15.89 |
| 03:59 ET | 2352 | 15.88 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Annovis Bio Inc | 124.5M | -4.6x | --- |
Anixa Biosciences Inc | 125.2M | -8.8x | --- |
Inozyme Pharma Inc | 122.8M | -1.3x | --- |
INmune Bio Inc | 123.6M | -4.4x | --- |
Genenta Science SPA | 113.4M | -28.4x | --- |
Nanobiotix SA | 121.1M | -2.6x | --- |
Company Information
Annovis Bio, Inc. is a clinical-stage drug platform company. The Company is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The Company's lead compound, Buntanetap, is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS. The Company's ANVS405 compound is being developed for acute indications, focused on protecting the brain after Traumatic brain injury (TBI) and/or stroke. Its ANVS405 is the same compound as Buntanetap, but it is given intravenously in cases of acute head and brain trauma. The Company is also developing its compound, ANVS301 to increase cognitive capability in later stages of AD and dementia.
Contact Information
- Headquarters
- 1055 Westlakes Dr Ste 300BERWYN, PA, United States 19312-2410
- Phone
- 610-727-3913
- Fax
- 610-727-4001
Executives
- Independent Chairman of the Board
- Michael Hoffman
- President, Chief Executive Officer, Founder, Director
- Maria Maccecchini
- Chief Financial Officer
- Henry Hagopian
- Independent Director
- Claudine Bruck
- Independent Director
- Reid McCarthy
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $124.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 8.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.45 |
Book Value | $5.49 |
P/E Ratio | -4.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
